CAM
YMAB

Cormorant Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Cormorant Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-425,000
Closed -$3.33M – 51
2024
Q4 		$3.33M Sell
425,000
-1,025,000
-71% -$12.5M 0.18% 41
2024
Q3 		$19.1M Hold
1,450,000
– – 1.01% 31
2024
Q2 		$17.5M Buy
+1,450,000
New +$19.6M 1.01% 29
2023
Q1 		– Sell
-150,000
Closed -$732K – 83
2022
Q4 		$732K Hold
150,000
– – 0.05% 69
2022
Q3 		$2.16M Hold
150,000
– – 0.15% 60
2022
Q2 		$2.27M Hold
150,000
– – 0.17% 61
2022
Q1 		$1.78M Sell
150,000
-150,000
-50% -$1.54M 0.14% 68
2021
Q4 		$4.86M Sell
300,000
-200,000
-40% -$4.27M 0.29% 55
2021
Q3 		$14.3M Sell
500,000
-300,000
-38% -$9.45M 0.58% 44
2021
Q2 		$27M Sell
800,000
-430,000
-35% -$13.8M 0.92% 30
2021
Q1 		$37.2M Sell
1,230,000
-431,647
-26% -$17.7M 0.83% 31
2020
Q4 		$82.3M Buy
1,661,647
+263,947
+19% +$12.2M 1.96% 13
2020
Q3 		$53.7M Sell
1,397,700
-176,983
-11% -$7.04M 2.06% 15
2020
Q2 		$68M Sell
1,574,683
-157,517
-9% -$5.96M 2.6% 9
2020
Q1 		$45.2M Buy
1,732,200
+129,824
+8% +$3.77M 2.1% 14
2019
Q4 		$50.1M Buy
1,602,376
+718,576
+81% +$21.3M 2% 18
2019
Q3 		$23M Sell
883,800
-116,200
-12% -$2.97M 1.4% 26
2019
Q2 		$22.9M Buy
1,000,000
+284,518
+40% +$6.53M 1.31% 25
2019
Q1 		$18.8M Buy
715,482
+520,714
+267% +$11.4M 1.27% 28
2018
Q4 		$3.96M Sell
194,768
-5,232
-3% -$120K 0.32% 55
2018
Q3 		$5.31M Buy
+200,000
New +$5.09M 0.35% 49

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cormorant Asset Management's YMAB Position: Q1 2025 in Review

Cormorant Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 425,000 shares — an estimated $3.33M sold.

Cormorant Asset Management first reported a position in YMAB in Q3 2018 and held it in 21 quarters. The position peaked at $82.3M in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Cormorant Asset Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 425,000 Y-mAbs Therapeutics shares in Q1 2025, an estimated $3.33M.
  • Cormorant Asset Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 21 quarters.
  • Cormorant Asset Management's Y-mAbs Therapeutics position peaked at $82.3M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.